RxDoctor Payments DataLook up a doctor →

Mazhar Khowaja

Psychiatry · Houston, TXNPI 1770523276

Payments from drug & device makers

$842,666in general payments, 2019–2025

Across 1,107 payments — averaging $761.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$467K
  • Neurocrine Biosciences, Inc.$374K
  • Otsuka America Pharmaceutical, Inc.$371
  • Teva Pharmaceuticals USA, Inc.$281
  • E.r. Squibb & Sons, L.L.C.$244
  • AbbVie$109
  • plus $111 from 3 others

What the payments were for

  • Consulting fees$60,6007%
  • Speaking & faculty fees$635,89275%
  • Travel & lodging$122,41915%
  • Food & beverage$23,7553%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$842,666 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$164,906
Medicare patients
249
Services billed
1,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate56$202,536
NuplazidPimavanserin Tartrate35$77,979
RexultiBrexpiprazole60$38,627
VraylarCariprazine Hcl15$14,827
CaplytaLumateperone Tosylate17$14,092
Memantine Hcl ErMemantine Hcl134$13,830
Rivastigmine47$8,166
Duloxetine Hcl168$5,432
Donepezil Hcl210$5,134
Aripiprazole36$4,508
Memantine Hcl135$4,276
Buspirone Hcl105$3,494
TrintellixVortioxetine Hydrobromide13$3,182
Divalproex Sodium48$2,675
Doxepin Hcl11$2,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$374,381$202,53656 claims
Acadia Pharmaceuticals IncNuplazid$467,169$77,97935 claims
Otsuka America Pharmaceutical, Inc.Rexulti$371$38,62760 claims
AbbVieVraylar$109$14,82715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →